Do Statins Improve Lung Function in Asthmatic Patients? ARandomized and Double-Blind Trial Role of statins in asthma
Iranian Journal of Pharmaceutical Sciences,
卷 5 编号 1 (2009),
15 January 2009
,
第 13-20 页
https://doi.org/10.22037/ijps.v5.41143
摘要
There are evidences that statins have anti-inflammatory effects beyond their cholesterol lowering properties. The study was conducted to assess the effects of atorvastatin on asthma as an inflammatory disease. Patients with moderate to sever easthma were entered this randomized, double blind, crossover clinical trial. The impact of oral atorvastatin (10 mg/day) on the lung function of normolipidemic patients was studied. The study was conducted in the National Research Institute of Tuberculosis and Lung Disease. Patients were randomized to receive either atorvastatin or placebo for 4 weeks separated by a 2-week washout period in a crossover fashion.Patients continued on their usual asthma drug treatment throughout the study.Spirometric parameters were determined at baseline and at completion of drug or placebo administration. Seventeen patients with the age of 37.12±12.41 years completed the trial. Data analysis revealed no significant differences in peak expiratory flow rate (PEF), forced expiratory volume in the first second (FEV1),forced vital capacity (FVC) and FEV1/FVC between placebo and atorvastatin therapy. The results showed no significant improvement in the pulmonary function tests in asthmatic patients receiving atorvastatin. Further studies using higher doses of statins and/or higher period of statin use are recommended.
- Asthma
- Atorvastatin
- Clinical trials
- Lung Function
- Statin
##submission.howToCite##
参考
[2]Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: Ameta-analysis of randomized controlled trials. Am J Med2004;117: 596-606.[3]Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against in flammatory processes innormocholesterolemic rats. Arterioscler Throm Vasc Biol1999; 19: 2894-900.
[4]Joukhadar C, Klein N, Prinz M, Schrolnberger C,Vukovich T, Wolzt M, Schmetterer L, Dorner GT. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.Thromb Haemost2001; 85: 47-51.
[5]Ikeda U, Shimada K. Statins and monocytes.Lancet1999; 353: 2070.
[6]Hothersall E, McSharry C, Thomson NC.Potential therapeutic role for statins in respiratory diseases. Thorax2006; 61: 729-34.
[7]Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin.Lancet1999; 353: 983-4.
[8]Weitz-Schmit G, Welzenbach K, Brinkmannn V,Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding a novel regulatory integrin site. Nat Med2001; 7: 687-92.
[9]Kwak B, Mulhaupt F, Myit S, Mach F. Statins as newly recognized type of immunomodulator. Nat Med2000; 6:1399-1402.
[10]McKay A, Leung BP, McInnes IB, Thomson NC,Liew FY. Anovel anti-inflammatory role of simvastatin in a murine model of asthma. JImmunol2004; 172: 2903-8.
[11]Kim DY, Ryu SY, Lim JE, Lee YS, Ro JY. Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model.Eur J Pharmacol2007;557: 76-86.
[12]Katznelson S, Wang XM, Chia D, Ozawa M,Zhong HP, Hirata M, Terasaki PI, Kobashigawa JA. The inhibitory effects of pravastatin on natural killer cell activityin vivoand on cytotoxic T lymphocyte activityin vitro. J Heart Lung Transplant 1998; 17: 335-40.
[13]Wei H, Zhang J, Xiao W, Feng J, Sun R, Tian Z.Involvement of human natural killer cells in asthma pathogenesis: Natural killer 2 cells in type 2 cytokine predominance. J Allergy ClinImmunol2005; 115: 841-7.[14]Laufs U, La Fata V, Plutzky J, Liao JK.Upregulation of endothelial nitric oxide synthase by HMG CoAreductase inhibitors. Circulation1998; 97: 1129-35.
[15]Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G.Nitric oxide in health and disease of the respiratory system. Physiol Rev2004; 84: 731-65.
[16]Larsson AK, Bäck M, Hjoberg J, Dahlén SE.Inhibition of nitric-oxide synthase enhances antigen-induced contractions and increases release of cysteinyl-leukotrienes in guinea pig lung parenchyma: Nitric oxide as a protective factor.J Pharmacol Exp Ther 2005; 315: 458-65.
[17]Menzies D, Nair A, Meldrum KT, Fleming D,Barnes M, Lipworth BJ. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma.J Allergy Clin Immunol 2007; 119: 328-35.
[18]Kiener PA, Davis PM, Murray JL, Youssef S,Rankin BM, Kowala M. Stimulation of inflammatory responsesin vitroand in vivobylipophilic HMG-CoAreductase inhibitors. Int Immunopharmacol2001; 1: 105-18.[19]Hilgendorff A, Muth H, Parviz B, Staubitz A,Haberbosch W, Tillmanns H, Hölschermann H.Statins differ in their ability to block NF-kBactivation in human blood monocytes. Int J Clin Pharmacol Ther2003; 41: 397-401.
[20]Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI,Riesen WF, Rickli H, Wüthrich RP, Ammann P.Statin-induced immunomodulatory effects on human Tcells in vivo. Atherosclerosis2004; 175:83-90.
[21]US National Institute of Health (Date last updated:August 2, 2006. Date last accessed: September 11,2006) Effect of statins on asthma control in smokers with asthma: Pilot study of effect of statins on lung function in COPD.http://clinicaltrials.gov.
[22]US National Institute of Health (Date last updated:February 14, 2006. Date last accessed: September 11, 2006) Statin treatment in patients with asthma.http://clinicaltrials.gov.
[23]Yeh YF, Huang SL. Enhancing effect of dietary cholesterol and inhibitory effect of pravastatin on allergic pulmonary inflammation. J Biomed Sci 2004; 11: 599-606.
[24]Lee JH, Lee DS, Kim EK, Choe KH, Oh YM,Shim TS, Kim SE, Lee YS, Lee SD. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172: 987-93.
[25]Lawman S, Mauri C, Jury EC, Cook HT,Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol2004; 173: 7641-6.[26]Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbell C, Gracie JA, Liew FY, McInnes IB. Anovel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30.
[27]Erikstrup C, Ullum H, Pedersen BK. Short-term simvastatin treatment has no effect on plasma cytokine response in a human in vivomodel of low-grade inflammation. Clin Exp Immunol2006;144: 94-100.[28]Ikeda U, Shimpo M, Ohki R, Inaba H, Takahashi M, Yamamoto K, Shimada K. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension2000;36: 325-9.
- 摘要 ##plugins.themes.ojsPlusA.frontend.article.viewed##: 77 ##plugins.themes.ojsPlusA.frontend.article.times##
- IJPS_Volume 5_Issue 1_Pages 13-20 (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 18 ##plugins.themes.ojsPlusA.frontend.article.times##